Efficacy of Abatacept for Arthritis in Patients with an Overlap Syndrome between Rheumatoid Arthritis and Systemic Lupus Erythematosus

Table 2

Disease characteristics of SLE before abatacept treatment.

Case number	Duration of SLE (month)	Major current disease manifestations other than arthritis	Major previous disease manifestations other than arthritis	CTD other than RA or SLE	ANA	Anti-DNA antibody (U/mL)	Other autoantibodies	IgG (mg/dL)	C3 (mg/dL)	C4 (mg/dL)	CH50 (U/mL)	SLEDAI
1	2	Low grade fever, rash, anemia, leukocytopenia	Fever, rash, anemia, leukocytopenia	SS, chronic thyroiditis	>1280	29.5	Ro, LA, TPO	2285	81	14	36.8	7
2	565	Rash	Rash, leukocytopenia, pericarditis, pleuritis	SS	>1280	47.8	Ro, La	1265	87	12	31.1	12
3	20	None	Fever, anemia, leukocytopenia	None	320	28.3	U1-RNP, Cardiolipin	1939	27	3	<5.0	8
4	151	Rash	Rash, leukocytopenia	Scleroderma, chronic thyroiditis	>1280	16.8	Sm, U1-RNP, TPO	1625	111	41	47.5	6
5	420	None	Fever, rash, severe thrombocytopenia	SS	160	10.1	Ro, La	2285	66	4	17.4	6
6	96	None	Fever, rash, myositis, ILD	SS	320	4.0	U1-RNP, Ro	1598	152	40	45.1	4

SLE: systemic lupus erythematosus; CTD: connective tissue disease; ANA: antinuclear antibody; IgG: immunoglobulin G; SLEDAI: systemic lupus erythematosus disease activity index; ILD: interstitial lung disease; SS: Sjogren’s syndrome; APS: antiphospholipid syndrome; LA: lupus anticoagulant; TPO: thyroid peroxidase; RNP: ribonucleoprotein.